Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years — IVY Network, 18 States, September 8–November 30, 2022

Title: Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years — IVY Network, 18 States, September 8–November 30, 2022
Authors: Surie, Diya; DeCuir, Jennifer; Zhu, Yuwei; Gaglani, Manjusha; Ginde, Adit A; Douin, David J; Talbot, H Keipp; Casey, Jonathan D; Mohr, Nicholas M; Zepeski, Anne; McNeal, Tresa; Ghamande, Shekhar; Gibbs, Kevin W; Files, D Clark; Hager, David N; Ali, Harith; Taghizadeh, Leyla; Gong, Michelle N; Mohamed, Amira; Johnson, Nicholas J; Steingrub, Jay S; Peltan, Ithan D; Brown, Samuel M; Martin, Emily T; Khan, Akram; Bender, William S; Duggal, Abhijit; Wilson, Jennifer G; Qadir, Nida; Chang, Steven Y; Mallow, Christopher; Kwon, Jennie H; Exline, Matthew C; Lauring, Adam S; Shapiro, Nathan I; Columbus, Cristie; Halasa, Natasha; Chappell, James D; Grijalva, Carlos G; Rice, Todd W; Stubblefield, William B; Baughman, Adrienne; Womack, Kelsey N; Rhoads, Jillian P; Hart, Kimberly W; Swan, Sydney A; Lewis, Nathaniel M; McMorrow, Meredith L; Self, Wesley H; Network, IVY
Source: MMWR Morbidity and Mortality Weekly Report, vol 71, iss 5152
Publisher Information: eScholarship, University of California
Publication Year: 2022
Collection: University of California: eScholarship
Subject Terms: 32 Biomedical and Clinical Sciences (for-2020); 3202 Clinical Sciences (for-2020); Coronaviruses (rcdc); Prevention (rcdc); Emerging Infectious Diseases (rcdc); Biotechnology (rcdc); Infectious Diseases (rcdc); Aging (rcdc); Vaccine Related (rcdc); Coronaviruses Disparities and At-Risk Populations (rcdc); Immunization (rcdc); Lung (rcdc); 3.4 Vaccines (hrcs-rac); 3 Good Health and Well Being (sdg); Humans (mesh); Aged (mesh); COVID-19 (mesh); SARS-CoV-2 (mesh); COVID-19 Vaccines (mesh); Vaccine Efficacy (mesh); Hospitalization (mesh); RNA; Messenger (mesh); Vaccines; Combined (mesh); IVY Network; General & Internal Medicine (science-metrix)
Time: 1625 - 1630
Description: Monovalent COVID-19 mRNA vaccines, designed against the ancestral strain of SARS-CoV-2, successfully reduced COVID-19-related morbidity and mortality in the United States and globally (1,2). However, vaccine effectiveness (VE) against COVID-19-associated hospitalization has declined over time, likely related to a combination of factors, including waning immunity and, with the emergence of the Omicron variant and its sublineages, immune evasion (3). To address these factors, on September 1, 2022, the Advisory Committee on Immunization Practices recommended a bivalent COVID-19 mRNA booster (bivalent booster) dose, developed against the spike protein from ancestral SARS-CoV-2 and Omicron BA.4/BA.5 sublineages, for persons who had completed at least a primary COVID-19 vaccination series (with or without monovalent booster doses) ≥2 months earlier (4). Data on the effectiveness of a bivalent booster dose against COVID-19 hospitalization in the United States are lacking, including among older adults, who are at highest risk for severe COVID-19-associated illness. During September 8-November 30, 2022, the Investigating Respiratory Viruses in the Acutely Ill (IVY) Network§ assessed effectiveness of a bivalent booster dose received after ≥2 doses of monovalent mRNA vaccine against COVID-19-associated hospitalization among immunocompetent adults aged ≥65 years. When compared with unvaccinated persons, VE of a bivalent booster dose received ≥7 days before illness onset (median=29 days) against COVID-19-associated hospitalization was 84%. Compared with persons who received ≥2 monovalent-only mRNA vaccine doses, relative VE of a bivalent booster dose was 73%. These early findings show that a bivalent booster dose provided strong protection against COVID-19-associated hospitalization in older adults and additional protection among persons with previous monovalent-only mRNA vaccination. All eligible persons, especially adults aged ≥65 years, should receive a bivalent booster dose to maximize protection against COVID-19 ...
Document Type: article in journal/newspaper
File Description: application/pdf
Language: unknown
Relation: qt2n94p6qx; https://escholarship.org/uc/item/2n94p6qx; https://escholarship.org/content/qt2n94p6qx/qt2n94p6qx.pdf
DOI: 10.15585/mmwr.mm715152e2
Availability: https://escholarship.org/uc/item/2n94p6qx; https://escholarship.org/content/qt2n94p6qx/qt2n94p6qx.pdf; https://doi.org/10.15585/mmwr.mm715152e2
Rights: public
Accession Number: edsbas.6A60C57F
Database: BASE